Envestnet Portfolio Solutions
SUPN icon

Envestnet Portfolio Solutions’s Supernus Pharmaceuticals SUPN Stock Holding History

Envestnet Portfolio Solutions’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-7,324
Closed -$265K – 1756
2024
Q4 		$265K Buy
7,324
+39
+0.5% +$1.37K ﹤0.01% 1559
2024
Q3 		$227K Buy
+7,285
New +$227K ﹤0.01% 1579
2024
Q2 		– Sell
-9,188
Closed -$313K – 1690
2024
Q1 		$313K Sell
9,188
-33
-0.4% -$983 ﹤0.01% 1332
2023
Q4 		$267K Sell
9,221
-294
-3% -$7.79K ﹤0.01% 1355
2023
Q3 		$262K Buy
+9,515
New +$290K ﹤0.01% 1296

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

Envestnet Portfolio Solutions's SUPN Position: Q1 2025 in Review

Envestnet Portfolio Solutions sold out of Supernus Pharmaceuticals (SUPN) in Q1 2025, closing a stake of 7,324 shares — an estimated $265K sold.

Envestnet Portfolio Solutions first reported a position in SUPN in Q3 2023 and held it in 5 quarters. The position peaked at $313K in Q1 2024. 295 funds tracked by Wall St. Rank hold SUPN as of Q1 2025.

  • Envestnet Portfolio Solutions reported no remaining Supernus Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Envestnet Portfolio Solutions sold 7,324 Supernus Pharmaceuticals shares in Q1 2025, an estimated $265K.
  • Envestnet Portfolio Solutions first reported a position in Supernus Pharmaceuticals in Q3 2023 and held it in 5 quarters.
  • Envestnet Portfolio Solutions's Supernus Pharmaceuticals position peaked at $313K in Q1 2024.
  • 295 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2025.

Based on Envestnet Portfolio Solutions's 13F filing for Q1 2025, filed 21 Apr 2025.